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The effects of frequency, intensity, duration and volume of walking interventions 
on CVD risk factors: A systematic review and meta-regression analysis of 
randomized controlled trials among inactive healthy adults 
 
Pekka Oja, Paul Kelly, Elaine Murtagh, Marie Murphy, Charlie Foster, Sylvia Titze 
Abstract 
Objective. Walking interventions in healthy populations show clinically relevant improvements for 
many cardiovascular disease (CVD) risk factors. We aimed to assess the changes in CVD risk factors 
and the dose-response relationship between frequency, intensity, duration and volume of walking 
based on randomized controlled trials (RCTs). 
Design. A systematic review with meta-analysis and meta-regression. 
Data sources.  Four electronic databases searched from January 1971 to April 2017.   
Eligibility criteria. Walking RCTs reporting one or more CVD risk factor outcomes; trials including 
at least one group with walking intervention and a no-walking control group; duration ≥8 weeks; 
participants ≥18 years old, inactive but healthy; risk factors assessed pre- and post-intervention; 
English language articles in peer-reviewed journals. 
 
Results. Thirty-seven RCTs, involving 2001 participants (81% women), and assessing 13 CVD risk 
factors were identified. Pooled meta-analysis showed favorable effects (p≤0.05) of walking 
intervention for seven CVD risk factors (body mass, BMI, body fat, systolic and diastolic blood 
pressure, and fasting glucose, and VO2max). There were no significant effects (p>0.05) for waist 
circumference, waist-to-hip ratio, and four blood lipid variables. 
Despite testing 91 possible dose-response relationships, linear meta-regression analysis adjusted 
for age indicated just 7 (or 7.7%) statistically significant findings.  
Summary/conclusion. Walking interventions benefit a number of CVD risk factors. Despite 
multiple studies and tested metrics only a few dose-response relationships were identified and the 
possibility of chance findings cannot be ruled out. There is  insufficient evidence to quantify the 
frequency, length, bout duration, intensity, and volume of the walking required to improve CVD 
risk factors. 
 
word count: 250 
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INTRODUCTION 
Non-communicable diseases (NCD) are a major burden worldwide 1. It has been estimated that 
elimination of physical inactivity would remove between 6% and 10% of the major NCDs of 
coronary heart disease (CHD), type 2 diabetes, and breast and colon cancers, and increase life 
expectancy2. One key approach to increase population levels of physical activity is to promote 
safe, accessible, and environmentally friendly activity options for all citizens, including improved 
infrastructure for walking and cycling for transport and recreation3. 
 
Walking is the ideal physical activity intervention to improve health across the population4. A 
recent systematic review of 32 randomized controlled trials by Murtagh et al. (reference) showed 
that walking increases aerobic capacity and reduces blood pressure, waist circumference, body 
weight, percent body fat and body mass index.  Another systematic review (Hanson and Jones 
2015) reported similar health benefits of recreational walking including reduced systolic and 
diastolic blood pressure, resting heart rate, body fat, body mass index and total cholesterol, and 
increased VO2max, physical functioning and the distance covered in a 6-min walk-test.  
National physical activity recommendations are based on summative volumes of different 
intensities of physical activity over a week, with walking as the cornerstone of health promotion 
efforts. However, walking can vary considerably in terms of the frequency, intensity, daily/weekly 
duration, and total volume. Specific evidence on the dose-response relationships could increase 
health professionals’ effectiveness in promoting physical activity, and specifically walking for 
health benefits. 
Observational data indicate some dose response relationships at a population level. In a 
systematic review of epidemiological studies with all-cause mortality as the endpoint Hamer et al. 
(2008) found that walking pace was a stronger independent predictor than walking volume. 
Through meta-analysis Kelly at al.5 showed an increased reduction in the risk of all-cause mortality 
for higher walking volumes (in MET-hours per week). Also randomized controlled walking trials 
have found some dose-response relationships.  Asikainen et al. (2002a) searched for the minimum 
dose of walking for health benefits and found that a weekly dose of 1000 to 1500 kcal of walking  
improved the aerobic power and body composition of previously sedentary non-obese post-
menopausal women. Recently anson and Jones6  noted based on their systematic review of 
randomized controlled walking trials that there is insufficient evidence to suggest any conclusions 
about the dose-response between the volume and intensity of walking and the health outcomes.  
CVD risk factor reduction via walking promotion must be based not only on evidence of 
effectiveness but also on being able to identify the effects of variations in different characteristics 
of walking, potentially offering more options for walking. Based on the updated data of Murtagh 
et al (reference) our systematic review aimed to  (1) update the evidence for the effects of walking 
interventions on CVD risk factors and in particular to  (2) study the dose-response relationships 
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between the frequency, intensity, duration and volume of walking interventions and CVD risk 
factors in healthy inactive adults. 
METHODS 
Registration 
This study is registered in PROSPERO as CRD42016039409. 
Data search 
 
Studies (1971-2012) included in an earlier systematic review7, were supplemented by electronic 
searches (January 2012 – April 2017) of 4 databases: Cochrane Central Register for Controlled 
Trials, Medline, Web of Science and SPORTDiscus. The following search terms were used in both 
searches (1) walking, (2) exercise, (3) health, (4) cardiovascular risk. The full search strategy for the 
2012-2017 search is enclosed as “Supplementary file”. Reference lists from review and original 
articles were hand-searched for additional studies.  
 
Eligibility criteria 
 
Studies were selected based on the following inclusion/exclusion criteria: randomized controlled 
trials (RCTs) studying the effects of walking on one or more CVD risk factors; trials with at least one 
group completing walking as the only intervention; intervention duration at least 8 weeks; control 
group with no walking intervention; participants aged 18 years or older who were insufficiently 
active but otherwise healthy and capable of unaided walking (otherwise no other age limit); CVD 
risk factors assessed pre- and post-training (or change from pre- to post-intervention reported); 
English language articles published in peer-reviewed journals between January 1971 and April 
2017. 
 
Study selection 
 
Twenty-eight studies (Aldred 1995, Anderson 2006, Asikainen 2002a, Asikainen 2002b, Baker 
2008, Bell 2010, Braith 1994, Brandon 2006, Butcher 2008, Duncan 1991, Hinkleman 1993, Jette 
1998, Moreau 2001, Morgan 2010, Murphy 1998, Murphy 2006, Murtagh 2005, Probart 1991, 
Ready 1995, Ready 1996, Santiago 1995, Serwe 2011, Stensel 1993, Stensel 1994, Tully 2005, Tully 
2007, Woolf-May 1999, Woolf-May 2011) from previous review (Murtagh et al. 2015) of 32 studies 
were included in the current analyses. Two studies were excluded because of very old age of the 
participants 8 9 and two studies because of insufficient outcome data 10 11. Screening of the 
previous review is described elsewhere 7. The updated search resulted in 10 new studies for 
inclusion (Foulds 2014, Gaba 2016, Hamdorf 1992, Herzig 2014, Hong 2014, Jasinski 2015, Kang 
2014, Kearney 2014, Pospieszna 2017, Zhang 2014). Titles and abstracts from the updated search 
were screened by three authors (PO, ST, PK). Full papers were screened independently for 
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eligibility by two authors (PO, ST and PO, PK). Disagreements were resolved by jointly reassessing 
the studies against the eligibility criteria.  
 
Data extraction  
 
Two authors (PO, PK) extracted participant characteristics and outcome measures data 
independently and a third author (ST) checked the extracted data of all included studies. 
Disagreements were resolved by consensus. Dose attributes were defined as frequency, intensity, 
duration and total volume of walking, and the health outcomes for CVD risk factors as measures of 
cardio-metabolic fitness, adiposity and blood lipid profile. Intervention dose metrics were 
extracted by one author (PO) and cross-checked by a second author (ST). Missing information was 
sought from the authors of twelve studies 10-21. 
 
Intervention dose metrics were: frequency (sessions per week), duration of the intervention 
(weeks), bout duration (minutes per session), intensity as METs and %VO2max, and volume as 
MET-minutes per week, and total MET-hours, (conversion formulas are indicated in the respective 
tables 22-24). The outcome measures were: aerobic fitness expressed as VO2max (ml*kg-1*min-1), 
body mass (kg), body fat (%), body mass index (weight in kilograms divided by height in meters2), 
waist circumference (cm), waist-to-hip-ratio, systolic and diastolic blood pressure (mmHg), total 
cholesterol (mmol*L-1), HDL cholesterol (mmol*L-1), LDL cholesterol (mmol*L-1), triglycerides 
(mmol*L-1), and fasting glucose(mmol*L-1) . Outcomes for insulin resistance and inflammation-
related serum cytokines 25, blood flow in lower extremities 26, arterial stiffness21, postural stability 
27, bone mineral density 27, and biomarkers of endothelial function 28 were not included in the 
meta-analyses because of insufficient number of comparisons (<10) (see ref 29).  
 
Assessment of the risk of bias 
  
Risk of bias of individual studies was assessed by the Cochrane Collaboration tool 29. Two authors 
(PO, EM) assessed studies independently for sequence generation, allocation concealment, 
blinding, incomplete outcome data, selective outcome reporting, and other potential threats to 
validity. Divergent ratings were re-assessed independently by a third author (MM) to reach 
consensus.  
 
Synthesis of results 
 
The software “Comprehensive Meta-Analysis” was used for all statistical analyses 30. For each CVD 
risk factor outcome, standardized mean difference (SMD) (defined as the raw difference between 
the mean change in the intervention group and the mean change in the control group divided by 
pooled post standard deviation (SD)) was used as the summary measure. When these data were 
not reported, we used the reported findings as follows. For the studies by Butcher et al. 19, 
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Murphy et al. 18, and Tully et al. 15 16 we used mean change and its SD and the number of 
participants in each group to calculate SMD. For the study of Hamdorf et al. 31 we used pre and 
post means and the number of participants in each group and F for the difference between 
changes. For body mass in the study by Hinkleman et al. 32 the number of participants in each 
group and F for difference between the changes were used in the formula. 
Eleven studies included more than one walking intervention group. The results for each group 
compared to the control were treated as independent studies. The number of participants in the 
control group was divided by the number of intervention groups 29. The effect direction was set 
negative for studies where a decrease represented an improvement in the health risk factor 
compared to the control group, and the effect direction was set positive for HDL cholesterol and 
VO2max as an increase represents an improvement in health risk. The following Q statistics were 
used to identify and quantify the heterogeneity in effect sizes for each CVD outcome: (1) the 
estimated standard deviation of the true effect size (Tau); (2) the ratio of true heterogeneity to 
total variation in observed effects (I2), which can range from 0% to 100%; and (3) the p-value to 
test the null-hypothesis that all studies share a common effect size 30. Publication bias was 
assessed by visual inspection of funnel plots. If a publication bias was assumed cumulative forest 
plots 30 were used for confirmation. 
Effect sizes were expressed in the original units of the outcome variables by multiplying SMD by a 
population representative standard deviation for the outcome 29. Representative standard 
deviations were obtained from the MONICA Population Survey data 33 for body mass, BMI, waist 
circumference, systolic and diastolic blood pressure and total and HDL cholesterol. For VO2max the 
SD was taken from a Norwegian study of 3816 participants 34, and for percent body fat from the 
FINNRISK 2007 study 35.  
All analyses were adjusted for age. Sex was not considered a confounder because only two studies 
were male only. Further adjustment for sex indicated that there was no difference in the effect 
sizes between subgroups with females only, males only, mixed and no information.  
Dose-response by walking characteristics 
We conducted random-effects univariate meta-regression analysis with adjustment for age using 
continuous walking intervention characteristics as the covariates to test linear as well as 
curvilinear relationships. The dependent variable was the SMD for each CVD-outcome. In the 
regression models the study’s weight was the inverse of the total variance for each CVD-outcome.  
Meta regression results are reported as the linear ß-coefficient with 95% CI and p-values. The 
curvilinear regressions between the MET-related doses and the outcomes were analysed by 
creating two variables (dose minus mean and dose minus mean squared) and testing if the 
interaction was significant. The Bonferroni correction (Field 2012) was applied to interpret the 
multiple comparison p-values. 
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RESULTS 
Selection of studies 
We searched four electronic  databases from 2012 – April 2017 to update the data of the previous 
systematic review (Murtagh et al 2015). The search resulted in a total of 7862 records. The 
screening of the titles and abstracts yielded 37 papers for potential inclusion. These were 
supplemented by 28 papers from the previous  review 7 and one paper was identified by hand 
searching. The full-text versions of 70 papers were then screened. Thirty-two papers were 
excluded due to the following reasons: mixed training content (7), non- or group-randomized 
design (8), non-healthy participants (8), no no-walking control group (3), incomplete outcome data 
(4), and unclear intervention (2). Thirty-eight eligible studies were included in the analyses. This 
included 28 studies from the previous review and 10 new studies. Where studies reported results 
using the same participants in more than one article these were combined to represent one study 
in the meta-analysis. Study selection is depicted in Figure 1.  
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Study characteristics 
 
Participant characteristics, study characteristics and walking intervention characteristics (session 
duration, frequency, and intensity as well as length of the intervention) for all 37 included studies 
are shown in supplementary table 1. In brief, 22 studies 18 20 25-28 31 32 36-40 43 44 48 52-56 58 included only 
women, three studies 13 14 17 only men, and 14 studies 12 15 16 19 21 41 42 45-47 49-51 57 both sexes as 
participants. The mean age of participants ranged from 30 to 72 years. The studies included 55 
walking intervention groups. Thirty studies prescribed ordinary walking, four studies treadmill 
walking, two studies utilized Nordic walking, and one “trekking” intervention.  
 
Exposure metrics 
Intervention dose characteristics varied considerably (Supplementary table 1 and 2): total duration 
8 to 52 weeks, session duration 10 to 90 minutes, number of sessions per week 1 to 15.4, weekly 
duration 10 to 325 minutes, intensity 1.7 to 5.8 METs, total weekly volume 27 to 1300 MET-
minutes per week, total walking duration 130 to 10192 minutes, and total intervention volume 
5.85 to 576 MET-hours.  
 
Twenty studies reported walking intensity as either percentage of maximum heart rate (range: 50-
86 % HRmax) 13 14 17 18 36 37 44 50-52 55 57, percentage of VO2max (range 45-65%) 25 32 38 39 47 54 or 
percentage heart rate reserve (range 54-85 %) 42 53 56. Four studies reported that walking was “self-
paced” 19 41 48 49 and seven studies noted that walking intensity was at a “brisk pace” 12 15 16 21 27 43 
45. Additionally two studies measured the intensity as walking speed 46 58, and one study as HR 31, 
MET 26, RPE 20, and ventilator threshold28, each.  
 
In ten studies 19 20 25 31 48-50 52 55 56 the intensity in METs could not be derived from the information 
provided, therefore intensity data are missing for these studies.  
Outcome data 
 
Our pooled data included sufficient number (≥10) of comparisons in the meta-analyses for body 
mass (40), BMI (28), body fat (28), waist circumference (18), waist-to-hip ratio (13), systolic blood 
pressure (34), diastolic blood pressure (32), total cholesterol (37), HDL cholesterol (35), LDL 
cholesterol (34), triglycerides (34), fasting glucose (16), and VO2max (31). Overall, both the meta-
analyses and the meta-regression analyses included 13 or more comparisons. 
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Risk of bias 
 
Results of the assessment of the risk of bias according to the Cochrane Collaboration assessment 
tool are shown in the Supplementary table 3. Among the 37 studies only two studies were 
assessed as being at low risk of bias across all domains 12 15.  
 
Meta-analysis 
 
Pooled meta-analysis results (SMD, 95% confidence intervals, p-value) are shown in Table 1. 
Significant favorable effects (p<0.05) were seen for body mass, BMI, body fat, systolic and diastolic 
blood pressure, fasting glucose, and VO2max. Estimated effect sizes were: body mass -1.6 kg, BMI -
0.60 kg*(m2)-1, systolic blood pressure - 4.05 mmHg, diastolic blood pressure -1.76 mmHg, and 
VO2max 4.86 ml*kg-1*min-1.  
 
Heterogeneity, as indicated by I2, was 0% for all outcomes except for systolic (17%) and diastolic 
(6%) blood pressure, total cholesterol (16%), and fasting glucose (23%).  
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Table 1. Meta-analysis on the effects of walking interventions on biomedical indices of health  
Outcome  
n 
Effect size Heterogeneity 
SDM 95% CI p  T I2 (%) p  
Body mass 42 -0.134 -0.233 to -0.034 0.009 0.000 0.000 1.000 
BMI  29 -0.142 -0.257 to -0.027 0.015 0.000 0.000 0.999 
Body fat  29 -0.216 -0.336 to -0.096 <0.001 0.000 0.000 0.999 
WC 18 -0.104 -0.265 to  0.058 0.208 0.000 0.000 0.998 
WHR 13 -0.165 -0.340 to  0.009 0.063 0.000 0.000 0.668 
SBP 35 -0.213 -0.344 to -0.082 0.001 0.164 17.981  0.178 
DBP 33 -0.166 -0.285 to -0.047  0.006 0.067 3.650 0.408 
TC 38 -0.123 -0.242 to  0.001 0.052 0.150 15.547 0.205 
HDL-C  36 0.035 -0.080 to  0.150 0.553 0.000 0.000 1.000 
LDL-C  35 0.030 -0.089 to  0.148 0.624 0.000 0.000 0.630 
TG 35 -0.084 -0.201 to  0.033 0.161 0.000 0.000 0.876 
FG 17 -0.211 -0.401 to -0.022 0.029 0.186 23.343 0.183 
VO2max 31 0.528  0.391 to  0.664 <0.001 0.000 0.000 0.715 
All estimates are from the meta-analysis using the random-effects model comparing an intervention 
group (walking) with a control group (no intervention) 
n = number of comparisons 
body mass (kg), BMI = body mass index (kg/m2), SBP = systolic blood pressure (mmol*L-1), DBP = diastolic 
blood pressure (mmol*L-1), TC = total cholesterol (mmol*L-1), HDL-C = high-density lipoprotein 
cholesterol (mmol*L-1), LDL-C = low-density lipoprotein cholesterol (mmol*L-1), TG = triglycerides 
(mmol*L-1), FG = fasting glucose (mmol*L-1), VO2max = maximal oxygen uptake  
SDM = standardized difference in means, CI = confidence interval, p-value for SDM (test of the null 
hypothesis that the effect is zero), T =Tau (estimate of the standard deviation in true effect sizes), I2 = 
heterogeneity (ratio of true heterogeneity to total observed variation), p-value  (test of the null 
hypothesis that all studies in the analysis share a common effect size) 
 
 
Funnel plots for the outcomes showed symmetric patterns suggesting non-significant publication 
bias except those for body fat and LDL (see supplementary file 1)). Cumulative forest plots of these 
outcomes (see supplementary file 1) showed symmetric pattern of the effect sizes even with the 
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less precise studies included, thus suggesting that there is no reason to assume a publication bias 
30.   
 
 
Meta regression and dose-response by walking dose characteristics 
 
The linear meta-regression analyses for (i) walking frequency (number of session per week), (ii) 
intervention duration (weeks) and (iii) session duration (minutes) showed three significant 
(p≤0.05) positive associations from 39 possible dose-response relationships [intervention duration 
with LDL-cholesterol (p=0.001) and VO2max (p=0.018), and session duration with triglycerides 
(p=0.029)], and one  inverse association [session duration with systolic blood pressure (p=0.050)] 
(table 2). 
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Table 2. Meta regression analysis: frequency, intervention duration, session duration (adjusted model#) 
Outcome Frequency, 
sessions per week 
Duration of intervention,  
weeks 
Duration of session,  
minutes 
n β 95% CI p n β 95% CI p n β 95% CI p 
Body mass 42 -0.0020 -0.0390 to 0.0429 0.924 42 0.0007 -0.0097 to 0.0110 0.898 39 -0.0016 -0.0077 to 0.0045 0.608 
BMI 29 -0.0068 -0.0552 to 0.0417 0.785 29 0.0008 -0.0111 to 0.0126 0.900 28 0.0018 -0.0051 to 0.0086 0.614 
Body fat 29 0.0136 -0.0542 to 0.0815 0.694 29 -0.0005 -0.0119 to 0.0110 0.938 26 -0.0024 -0.0094 to 0.0046 0.506 
WC 18 0.0041 -0.0523 to 0.0604 0.887 18 -0.0016 -0.0276 to 0.0244 0.903 18 -0.0009 -0.0127 to 0.0110 0.886 
WHR 14 0.0046 -0.1122 to 0.1215 0.938 14 0.0020 -0.0126 to 0.0164 0.785 14 0.0009 -0.0128 to 0.0145 0.899 
SBP 35 0.0418 -0.0058 to 0.0885 0.085 35 0.0073 -0.0153 to0.0288 0.527 34 -0.0075 -0.0150 to -0.000 0.050 
DPB 33 -0.0247  -0.0743 to 0.0249 0.328 33 0.0135 0.0061 to 0.0330 0.177 32 -0.0029 -0.0096 to 0.0039 0.408 
TC 38 0.0393 -0.0163 to 0.0950 0.166 38 0.0108 -0.0108 to 0.0233 0.093 35 -0.0038 -0.0114 to 0.0039 0.338 
HDL-C 36 0.0035 -0.0492 to 0.0562 0.895 36 0.0012 -0.0103 to 0.0127 0.838 33 -0.0004 -0.0102 to 0.0093 0.931 
LDL-C 35 0.0367 -0.0172 to 0.0905 0.182 35 0.0202 0.0081 to 0.0323 0.001 33 -0.0055 -0.0151 to 0.0040 0.256 
TG 33 -0.0004 -0.0534 to 0.0526 0.989 33 0.0000 -0.0183 to 0.0183 0.999 31 0.0077 0.0008 to 0.0146 0.029 
FG 17 -0.0420 -0.1372 to 0.0533 0.388 17 -0.0085 -0.0476 to 0.0306 0.671 16 -0.0062 -0.0170 to 0.0046 0.261 
VO2max 31 -0.0125 -0.0639 to 0.0389 0.633 31 0.0254 0.0043 to 0.0465 0.018 29 0.0071  -0.0024 to 0.0165 0.142 
 
# adjusted for age 
n = number of comparisons  
ß = linear regression coefficient, CI = confidence interval,  
Body mass (kg), BMI = body mass index [kg*(m2)-1], body fat (%), WC = waist circumferences (cm), WHR = waist to hip ratio, SBP = systolic blood pressure 
(mm Hg), DBP = diastolic blood pressure (mm Hg), TC = total cholesterol (mmol*L-1), HDL-C = high-density lipoprotein cholesterol (mmol*L-1), LDL-C = low-
density lipoprotein cholesterol (mmol*L-1), TG = triglycerides (mmol*L-1)), FG = fasting glucose (mmol*L-1), VO2max = maximal oxygen uptake (ml*kg-1*min-1) 
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The linear meta-regression analysis between the three MET related metrics (METs, MET-minutes 
per week, total MET-hours) and the outcomes resulted in three positive associations from a 
possible 39: METs with VO2max (p=0.049), MET-min per week with triglycerides (p=0.009), and 
total MET-hours with LDL-cholesterol (p=0.007)] (Table 3). We found one positive relationships to 
be significantly curvilinear after adjustment for multiple testing: intensity in METs with LDL-
cholesterol (results not shown).  
Respective linear analysis with the relative intensity dose (%VO2max) yielded one inverse 
association: %VO2max with diastolic blood pressure (p=0.020)] (Table 4). 
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Table 3. Meta regression analysis: MET-related doses (adjusted model#) 
Outcome  
n 
METs MET-minutes per week MET-hours total 
β 95% CI p β 95% CI p β 95% CI p 
Body mass  34 -0.0613 -0.1979 to 0.0752 0.378 -0.0002 -0.0005 to 0.0002 0.337 -0.0002 -0.0008 to 0.0005 0.640 
BMI 24 -0.0265 -0.2147 to 0.1617 0.782 -0.0000 -0.0004 to 0.0004 0.937 -0.0000 -0.0007 to 0.0007 0.961 
Body fat 23 -0.1309 -0.2927 to 0.0309 0.113 -0.0003 -0.0007 to 0.0001 0.163 -0.0002 -0.0009 to 0.0005 0.518 
WC 14 -0.1696 -0.4420 to 0.1023 0.222 -0.0003 -0.0011 to 0.0005 0.499 -0.0004 -0.0013 to 0.0011 0.572 
WHR 13 -0.0231 -0.3677 to 0.3215 0.896 0.0001 -0.0008 to 0.0011 0.763 0.0002 -0.0007 to 0.0011 0.678 
SBP 28 -0.0254 -0.2027 to 0.1519 0.779 0.0003 -0.0001 to 0.0007 0.154 0.0006 -0.0005 to 0.0016 0.270 
DPB 26 -0.1528 -0.3185 to 0.0129 0.071 -0.0001 -0.0006 to 0.0003 0.544 -0.0000 -0.0010 to 0.0010 0.988 
TC 33 0.1390 -0.0432 to 0.3213 0.135 0.0003 -0.0001 to 0.0007 0.148 0.0006 -0.0002 to 0.0013 0.133 
HDL-C 32 0.0391 -0.1233 to 0.2014 0.637 0.0001 -0.0003 to 0.0004 0.772 0.0001  -0.0006 to 0.0008 0.737 
LDL-C 32 0.1124 -0.0503 to 0.2751 0.176 0.0002 -0.0002 to 0.0006 0.292 0.0010 0.0003 to 0.0017 0.007 
TG 23 0.1251 -0.0384 to 0.2886 0.134 0.0005 0.0001 to 0.0009 0.009 0.0008 -0.0001 to 0.0018 0.086 
FG 14 -0.1564 -0.4049 to 0.0921 0.217 -0.0005 -0.0011 to 0.0000 0.064 -0.0010 -0.0025 to 0.0005 0.185 
VO2max 29 0.1612 0.0006 to 0.3218 0.049 0.0003 -0.0001 to 0.0008 0.115 0.0009 -0.0002 to 0.0020 0.106 
 
# adjusted for age 
n = number of comparisons  
ß = linear regression coefficient, CI = confidence interval,  
Body mass (kg), BMI = body mass index (kg/m2), body fat (%), WC = waist circumferences (cm), WHR = waist to hip ratio, SBP = systolic blood pressure (mm Hg), 
DBP = diastolic blood pressure (mm Hg), TC = total cholesterol (mmol*L-1), HDL = high-density lipoprotein cholesterol (mmol*L-1), LDL = low-density lipoprotein 
cholesterol (mmol*L-1), TG = triglycerides (mmol*L-1), FG = fasting glucose (mmol*L-1), VO2max = maximal oxygen uptake (ml*kg-1*min-1) 
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Table 4. Meta regression analysis: %VO2max dose (adjusted model#) 
Outcome  %VO2max dose 
n ß 95% CI p 
Body mass  23 -0.0051 -0.0228 to 0.0126 0.574 
BMI  14 -0.0073 -0.0362 to 0.0216 0.620 
Body fat  14 -0.0080  0.0318 to 0.0157 0.506 
WC  8  0.0180 -0.0338 to 0.0698 0.496 
WHR  5  0.0316 -0.0357 to 0.0989 0.357 
SBP  19 -0.0197 -0.0409 to 0.0015 0.068 
DBP  17 -0.0235 -0.0433 to -0.0037 0.020 
TC  19  0.0032 -0.0193 to 0.0257 0.781 
HDL-C  18 -0.0027 -0.0252 to 0.0197 0.812 
LDL-C  19  0-0017 -0.0223 to 0.0256 0.892 
TG  18  0.0068 -0.0158 to 0.0294 0.555 
FG  8 -0.0252 -0.0570 to 0.0066 0.120 
VO2max  24  0.0161 -0.0019 to 0.0342 0.080 
# adjusted for age 
n = number of comparisons  
ß = linear regression coefficient, CI = confidence interval,  
Body mass (kg), BMI = body mass index, body fat (%), WC = waist circumferences (cm), WHR = waist to 
hip ratio, SBP = systolic blood pressure (mmHg), DBP = diastolic blood pressure (mmHg), TC = total 
cholesterol (mmol*L-1), HDL = high-density lipoprotein cholesterol (mmol*L-1), LDL = low-density 
lipoprotein cholesterol (mmol*L-1), TG = Triglycerides (mmol*L-1), FG = fasting glucose (mmol*L-1), 
VO2max = maximal oxygen uptake (ml*kg-1*min-1) 
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DISCUSSION 
Despite multiple studies and tested metrics only a few significant dose-response relationships 
between the walking doses and the CVD outcomes were identified and the possibility of chance 
findings cannot be ruled out. This review suggests that there is insufficient evidence to quantify 
the frequency, length, bout duration, intensity, and volume of the walking required to improve 
CVD risk profile. 
 
Our meta-analysis showed  significant positive impact of walking on seven CVD risk factors; body 
mass, BMI, body fat, systolic and diastolic blood pressure, fasting glucose, and VO2max. These 
findings are consistent with those of Murtagh et al. 7 except that of waist circumference, for which 
they found a statistically significant effect but we did not, and the new finding of decreased fasting 
glucose in the present review.  
Murtagh et al. (2015) evaluated the clinical significance of their findings and concluded that the 
found increase in VO2max would account for 15% reduction in mortality, the decreased systolic 
and diastolic blood pressure for ten and seven % reduction in mortality, respectively, and the 
decreased in BMI for ?? reduction in ???. As the found  impacts in the current analyses were of 
greater magnitude  than reported by Murtagh et al7(2015), and there was the additional decrease 
of fasting glucose, the found changes in the CVD risk factors can be considered clinically 
substantial.  
There was no indication of publication bias in the cumulative Funnel Plots but the quality of 
studies was variable. Due to incomplete reporting the risk of bias in sequence generation, 
allocation concealment, and blinding could not be assessed for the majority (76 to 84 %) of 
studies. In contrast low risk of bias for outcome analysis and reporting, and for other potential 
sources of bias was assessed for the majority (65 to 95 %) of the included studies. These 
observations highlight the need for careful execution and full reporting of future walking trials 
according to the current quality criteria to ensure the validity of the findings. 
Adherence to the exercise protocol may have an impact on the reported outcome results. Actual 
adherence is likely to be smaller than intended, especially in long lasting interventions, and the 
difference may lead to overestimation of the dose needed for changes. In our data of 37 studies 
22 studies reported adherence rate and 15 did not. The reported adherence rates varied between 
67% and 100% with 17 studies reporting over 80% adherence. While it is possible that the non-
reporting studies had lower adherence the high rates in the majority of the studies suggest that 
the possible overestimation of the dose may not substantial. We performed post-hoc sub-group 
and mixed-effect analyses comparing studies with adherence rates over and below 90% for all 
study outcomes.  The results indicated  no statistically significant differences in any of the 
outcomes. 
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Sufficient sample sizes are needed for reliable results. We examined our data from this 
perspective by conducting  post-hoc sub-group and mixed-effects analyses comparing study group 
sizes over and below 20 (per study arm) for all outcome variables. The sub-group analysis 
indicated statistically significant differences between the two sample sizes for fasting glucose, 
systolic blood pressure and LDL-Cholesterol. Subsequent mixed-effects analyses showed no 
differences between the two groups for LDL-Cholesterol, and statistically significant differences for 
fasting glucose and systolic blood pressure. Overall the sample size affected only two of the 13 
outcomes, which may also be due to the multiple comparisons. 
 
In our study we have attempted to explore the dose-response between walking characteristics and 
CVD risk factors using meta-regression analysis. One assumption for the use of meta-regression is 
sufficient heterogeneity in the outcome effects, i.e. some of the variance across the included 
studies is real. We found some (4-23%) heterogeneity as measured by the statistic I2 in four and no 
heterogeneity in nine outcomes. This low level of heterogeneity may explain the fact that we 
found only a few statistically significant dose-response associations.  
 
Moreover, as the meta-regression analyses included multiple comparisons between the dose and 
the outcomes (each 13 comparisons) there is a risk of overestimating the statistical significance. A 
more conservative p-value for our multiple testing would be between p<0.004 to 0.002 according 
to Bonferroni 59. All but one (weeks of intervention with LDL) of the found p-values for the 
regressions were greater than this. We therefore did not find any evidence that the response of 
the CVD risk factors is associated with the walking dose characteristics used in this study.   
 
The dose of walking in METs represents the absolute intensity, which confers different levels of 
relative physiological load across individuals with different capacity. Thus a dose of 5 METs may 
mean 50% of the capacity of a person with good cardiorespiratory fitness and 80% of the capacity 
of a person with low fitness. This means that the METs intensity is only an estimate of the absolute 
but not the relative physiological stimulus. Physiological load relative to maximum is likely to be 
the key stimulus for many of the alterations in health outcomes being considered. We found one 
significant positive response (VO2max, p=0.049) for the METs dose. Maximal oxygen uptake is the 
gold standard for aerobic fitness. The percent level of VO2max of training represents a good 
measure of the relative physiological training stimulus. We had 20 studies with %VO2max intensity 
(reported or converted). In all these studies the training intensity was determined by individual 
heart rate monitoring (19 studies) or walking speed (1 study) derived from laboratory assessment. 
Thus the relative intensity dose was physiologically controlled at the group level. The regression 
analysis (Table 4) resulted in a significant (p=0.020) inverse association between the %VO2max 
dose and diastolic blood pressure. As this p-value does not reach the conservative significance p-
level of 0.004 59, the response of the CVD risk factors is likely to be independent also of the relative 
intensity dose. 
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In order to put our findings in the context of current physical activity recommendations we can 
use MET-minutes per week dose, which combines the frequency, bout duration and intensity, as 
the bases. WHO 60 recommends 150 minutes of moderate-intensity aerobic physical activity per 
week for health benefits.  Applying 3 METs as the lower limit of moderate-intensity activity, the 
weekly minimum recommended dose is 450 MET-minutes. Our results indicate that walking within 
the range of approximately 100 to 1300 MET-min per week can benefit CVD risk factors. Thus 
according to our results even less than the recommended amount of weekly walking (e.g. 450 
MET-minutes) may be health-promoting for inactive middle-aged and older people. This is in line 
with a recent evidence summary, which suggests that approximately 200 MET-min per week is 
sufficient for health benefits 61.  
  
 
Strengths and weaknesses 
 
Our systematic review including 38 studies published between 1971 and 2017 identified a large 
number of randomized controlled walking trials conducted according to a standard set of 
quantitative criteria. The data set consisted of 28 studies from a previous review (Murtagh et al. 
2015) and ten new studies. This data set included 2001 participants and 55 comparisons between 
intervention and control groups and a commonly accepted set of the most important CVD risk 
factors, allowing for rigorous meta-analysis of the main effects of walking, and yielding robust 
effect sizes in several outcomes. Extraction of clearly defined walking dose characteristics enabled 
unique meta-regression analysis for the dose-response between walking attributes and health 
outcomes. In addition, both the linear and the curvilinear relationships were tested. To our 
knowledge this is the first attempt to explore the dose-response patterns with meta-regression 
analysis of data from randomized controlled walking trials.  
 
The study is not without weaknesses. We were not able to perform an individual participant data 
analysis using the primary data for each study but relied on aggregated data across studies 
resulting in increasing intra and inter study heterogeneity, and potentially regression to the mean. 
The low level of heterogeneity of the changes in the outcomes across the studies may have limited 
the power to detect dose-response relationships. The used dose metrics had to be converted from 
a variety of respective measures leading in several cases to estimated levels of the dose. The 
quality of the included studies was variable. In particular the sequence generation, allocation 
concealment and blinding in the trials was less than adequate in many studies. This may attenuate 
the precision of the effect sizes, although the direction of the observed effects was consistent. 
Another weakness concerns the generalizability of the findings. Participants in the studies were 
mostly healthy but inactive women so direct applicability to men and individuals with pre-existing 
chronic disease may be questioned. However, based on recent evidence on the effects of PA on 
health and on the resulting PA recommendations there appears very few differences between 
women and men. Moreover, as 35 of the 38 studies came from Europe, United states, Canada and 
Australia the findings may not be applicable to lower and middle income countries. 
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SUMMARY AND CONCLUSIONS  
 
Meta-analysis of data from 37 randomized controlled walking trials revealed significant 
improvements in seven CVD risk factors: decreases in body mass, BMI, body fat, systolic and 
diastolic blood pressure, fasting glucose, and an increase in VO2max. The effect sizes indicate 
clinically important improvements in CVD risk profile. There were non-significant effects on six 
CVD risk factors: waist-hip ratio and waist circumference, and in total-, HDL-, and LDL-cholesterol 
and triglycerides.  
 
Our meta-regression analyses did not find associations between the observed effects on the CVD 
risk factors and the frequency, length, bout duration, intensity and volume of the walking training. 
These results suggest that any walking exposure within the dose range of the included studies is 
likely to be beneficial for cardiovascular health. Current practice, population health promotion and 
exercise referral should reflect this. As these controlled intervention studies were designed and 
implemented for healthy but inactive middle-aged and older women and men, the findings 
demonstrate the health potential of everyday walking for large segments of populations.  Walking 
still remains firmly a “best buy” for public health. 
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Figure caption: Selection of studies. 
 
